Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double‐injury model

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British Journal of Pharmacology

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bjp.0703287PMID 10807659PMCID PMC1572059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.

  2000cited by this paper
• Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.

  1999cited by this paper
• Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.

  1999cited by this paper
• The molecular biology of cyclic nucleotide phosphodiesterases.

  1999cited by this paper
• Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)*

  1999cited by this paper
• Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.

  1998cited by this paper
• Impact of cilostazol on intimal proliferation after directional coronary atherectomy.

  1998cited by this paper
• Activation of cAMP–PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury

  1997cited by this paper
• Reinjury of arterial lesions induces intimal smooth muscle cell replication that is not controlled by fibroblast growth factor 2.

  1997influential reference
• Repeated balloon injury of rat aorta. A model of neointima with attenuated inhibition by heparin.

  1997influential reference
• Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.

  1996cited by this paper
• Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury.

  1996cited by this paper
• Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina.

  1996cited by this paper
• Rotational atherectomy with adjunctive balloon angioplasty versus conventional percutaneous transluminal coronary angioplasty in type B2 lesions: results of a randomized study.

  1996cited by this paper
• Simvastatin releases Ca2+ from a thapsigargin-sensitive pool and inhibits InsP3-dependent Ca2+ mobilization in vascular smooth muscle cells.

  1996cited by this paper
• Swine model of coronary restenosis: effect of a second injury.

  1996cited by this paper
• Mechanisms of luminal enlargement and quantification of vessel wall trauma following balloon coronary angioplasty and directional atherectomy.

  1995cited by this paper
• Kinetics of smooth muscle cell proliferation and intimal thickening in a pig carotid model of balloon injury.

  1995cited by this paper
• Restenosis after Transluminal Coronary Angioplasty: A Risk Factor Analysis

  1995cited by this paper
• Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family).

  1995cited by this paper
• The Intima: Soil for Atherosclerosis and Restenosis

  1995cited by this paper
• Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells.

  1995cited by this paper
• Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells.

  1995cited by this paper
• Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: implications in the treatment of restenosis after angioplasty.

  1994cited by this paper
• Multiple cyclic nucleotide phosphodiesterases.

  1994cited by this paper
• Animal models of restenosis.

  1994cited by this paper
• Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.

  1994influential reference
• Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis.

  1994cited by this paper
• Repeated endothelial removal augments intimal thickening and attenuates EDRF release.

  1994cited by this paper
• Prevention of intimal proliferation by cilostamide

  1994cited by this paper
• Pathobiology of intimal hyperplasia

  1994cited by this paper
• Two major signal pathways linked.

  1993cited by this paper
• Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.

  1993cited by this paper
• Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate.

  1993cited by this paper
• 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.

  1993cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells.

  1993cited by this paper
• Inhibition by cAMP of Ras-dependent activation of Raf.

  1993cited by this paper
• Effect of Chronic Subcutaneous or Intramural Administration of Heparin on Femoral Artery Restenosis After Balloon Angioplast in Hypercholesterolemic Rabbits: A Quantitative Angiographic and Histopathological Study

  1992cited by this paper
• Experimental models of coronary artery restenosis.

  1992cited by this paper
• Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.

  1992cited by this paper
• Effectiveness of Recombinant Desulphatohirudin in Reducing Restenosis After Balloon Angioplasty of Atherosclerotic Femoral Arteries in Rabbits

  1991cited by this paper
• Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF

  1991cited by this paper
• Restenosis after transluminal coronary angioplasty: a risk factor analysis.

  1990cited by this paper
• Effects of smooth muscle cell derived growth factor (SDGF) in combination with other growth factors on smooth muscle cells.

  1989cited by this paper
• Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery.

  1989cited by this paper
• Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719.

  1988cited by this paper
• Effect of cilostazol on platelet aggregation and experimental thrombosis

  1988cited by this paper
• Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  1988cited by this paper
• Cell cycle-dependent inhibition of DNA synthesis by prostaglandin I2 in cultured rabbit aortic smooth muscle cells.

  1988cited by this paper
• Sequence of cellular responses in rabbit aortas following one and two injuries with a balloon catheter.

  1988cited by this paper
• Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand.

  1987cited by this paper
• Effect of cilostazol on platelet aggregation and experimental thrombosis.

  1985cited by this paper
• Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery

  1985cited by this paper
• Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.

  1984cited by this paper
• Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography

  1984cited by this paper
• Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.

  1979cited by this paper
• The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system.

  1958influential reference

• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Phosphodiesterase in heart and vessels: from physiology to diseases

  2023cites this paper
• A non-catalytic function of PI3Kγ drives smooth muscle cell proliferation after arterial damage

  2020cites this paper
• Ending Restenosis: Inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP

  2019cites this paper
• Novel short isoforms of adenylyl cyclase as negative regulators of cAMP production.

  2018cites this paper
• Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System

  2018cites this paper
• A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.

  2017cites this paper
• Investigating the Role of PDE4D1/2 in Vascular Smooth Muscle Cell Desensitization

  2016cites this paper
• Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasia

  2013cites this paper
• Chapter 57 – Cilostazol

  2013cites this paper
• Rôle des phophodiestérases dans la compartimentation subcellulaire de l'AMPc dans la cellule musculaire lisse vasculaire : étude des altérations dans l'insuffisance cardiaque

  2012cites this paper
• Lentiviral-Mediated shRNA Silencing of PDE4D Gene Inhibits Platelet-Derived Growth Factor-Induced Proliferation and Migration of Rat Aortic Smooth Muscle Cells

  2011cites this paper
• Inotropic and chronotropic effects of new cilostamide derivatives on isolated rat atria

  2011cites this paper
• Future prospective of phosphodiesterase-3 inhibitors as antithorombotic drug

  2011cites this paper
• Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility.

  2011cites this paper
• Phosphodiesterase 3A (PDE3A) Deletion Suppresses Proliferation of Cultured Murine Vascular Smooth Muscle Cells (VSMCs) via Inhibition of Mitogen-activated Protein Kinase (MAPK) Signaling and Alterations in Critical Cell Cycle Regulatory Proteins*

  2011cites this paper
• cAMP/cGMP Dual-Specificity Phosphodiesterases

  2010cites this paper
• The Cyclic GMP Modulators YC-1 and Zaprinast Reduce Vessel Remodeling Through Antiproliferative and Proapoptotic Effects

  2009cites this paper
• Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives as inotropic agents

  2009cites this paper
• NEW PROCEDURE FOR THE TOTAL SYNTHESIS OF CILOSTAMIDE

  2008cites this paper
• Isoeugenodilol inhibits smooth muscle cell proliferation and neointimal thickening after balloon injury via inactivation of ERK1/2 pathway.

  2008cites this paper
• Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Overview of PDEs and Their Regulation Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular Syste

  2007cites this paper
• 2.23 – Phosphodiesterases

  2007cites this paper
• Regulation and Function of Cyclic Nucleotide Phosphodiesterases in Vascular Smooth Muscle and Vascular Diseases

  2006cites this paper
• Regulation of PDE Expression in Arteries: Role in Controlling Vascular Cyclic Nucleotide Signaling

  2006cites this paper
• The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400362-JLR200

  2005cites this paper
• Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus.

  2005cites this paper
• Characterization of a New Double-Injury Restenosis Model in the Rat Aorta

  2005cites this paper
• Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4.

  2004cites this paper
• Transduction of peptide analogs of the small heat shock-related protein HSP20 inhibits intimal hyperplasia.

  2004cites this paper
• Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system.

  2003cites this paper
• Potentiation of C-type natriuretic peptide with ultrasound and microbubbles to prevent neointimal formation after vascular injury in rats.

  2003cites this paper
• Role of Phosphodiesterase 3 in NO/cGMP-Mediated Antiinflammatory Effects in Vascular Smooth Muscle Cells

  2003cites this paper
• Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues.

  2002cites this paper
• Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation

  2002cites this paper
• Cyclic Nucleotide Phosphodiesterase 1 C Promotes Human Arterial Smooth Muscle Cell Proliferation

  2002cites this paper
• PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of cyclic nucleotide-mediated signalling in cardiac myocytes

  2002cites this paper
• Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries.

  2001cites this paper